Nanotechnology for delivery of drugs to the brain for epilepsy
暂无分享,去创建一个
[1] M. Joshi,et al. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. , 2007, Advanced drug delivery reviews.
[2] S. Rapoport. Modulation of blood-brain barrier permeability. , 1996, Journal of drug targeting.
[3] M. Mayberg,et al. Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.
[4] R. North,et al. Implantable pumps for drug delivery to the brain , 1995, Journal of Neuro-Oncology.
[5] R. Müller. Colloidal Carriers for Controlled Drug Delivery and Targeting: Modification, Characterization, and In Vivo Distribution , 1991 .
[6] M. Zignani,et al. Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.
[7] C. Cho,et al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. , 2005, Cancer biotherapy & radiopharmaceuticals.
[8] P F Morrison,et al. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[9] J. Huwyler,et al. Drug transport to brain with targeted liposomes , 2005 .
[10] Peter Ramge,et al. Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.
[11] W. Pardridge,et al. Drug Delivery to the Brain , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[12] P. Parisi,et al. Calcium‐channel Blocker Verapamil Administration in Prolonged and Refractory Status Epilepticus , 2005, Epilepsia.
[13] W. Löscher,et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein , 2007, Neuropharmacology.
[14] Tycho Heimbach,et al. Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.
[15] Nicolas de Tribolet,et al. Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means , 1998 .
[16] J. Pardeike,et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. , 2007, Advanced drug delivery reviews.
[17] W. Olbricht,et al. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[18] M. Kubek,et al. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation , 1998, Brain Research.
[19] A. Vortmeyer,et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. , 2005, Journal of neurosurgery.
[20] Masoud Alasvand Zarasvand,et al. Effect of transient hippocampal inhibition on amygdaloid kindled seizures and amygdaloid kindling rate , 2002, Brain Research.
[21] Wolfgang Löscher,et al. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy , 2006, Neurobiology of Disease.
[22] Joseph D. Andrade,et al. Protein—surface interactions in the presence of polyethylene oxide: II. Effect of protein size , 1991 .
[23] W. Löscher,et al. Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[24] Betty M Tyler,et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats , 2002, Epilepsy Research.
[25] Jean-Christophe Olivier,et al. Drug transport to brain with targeted nanoparticles , 2011, NeuroRX.
[26] E. Aronica,et al. Expression of Multidrug Transporters MRP1, MRP2, and BCRP Shortly after Status Epilepticus, during the Latent Period, and in Chronic Epileptic Rats , 2005, Epilepsia.
[27] E. Neuwelt,et al. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.
[28] Raghu Raghavan,et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. , 2006, Neurosurgical focus.
[29] N. Barbaro,et al. MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.
[30] R. Langer,et al. Transport rates of proteins in porous materials with known microgeometry. , 1989, Biophysical journal.
[31] E. Oldfield,et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. , 2005, Journal of neurosurgery.
[32] E. Perucca,et al. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V) , 2001, Epilepsy Research.
[33] R. Fisher,et al. Focally injected adenosine prevents seizures in the rat , 2004, Experimental Neurology.
[34] L. Knapp,et al. Clinical Experience With Fosphenytoin in Adults: Pharmacokinetics, Safety, and Efficacy , 1998, Journal of child neurology.
[35] P. Pávek,et al. Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents , 2006, Epilepsia.
[36] L. Brannon-Peppas,et al. Optimization of Preparation Techniques for Poly(Lactic Acid-Co-Glycolic Acid) Nanoparticles , 2000 .
[37] W. Mark Saltzman,et al. New Methods for Direct Delivery of Chemotherapy for Treating Brain Tumors , 2006, The Yale journal of biology and medicine.
[38] J. C. Baayen,et al. Expression and Cellular Distribution of Multidrug Resistance–related Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2004, Epilepsia.
[39] M. Rogawski,et al. Prolonged Attenuation of Amygdala-Kindled Seizure Measures in Rats by Convection-Enhanced Delivery of the N-Type Calcium Channel Antagonists ω-Conotoxin GVIA and ω-Conotoxin MVIIA , 2007, Journal of Pharmacology and Experimental Therapeutics.
[40] P F Morrison,et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.
[41] R. Gonzalez,et al. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain , 2007 .
[42] J. Drewe,et al. Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System , 2000, Journal of drug targeting.
[43] M. Yıldırım,et al. Anticonvulsant effects of focal and intracerebroventricular adenosine on penicillin-induced epileptiform activity in rats , 2007, Brain Research.
[44] S. Krähenbühl,et al. Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects , 2005, Journal of drug targeting.
[45] Imad Najm,et al. Seizure‐Promoting Effect of Blood–Brain Barrier Disruption , 2007, Epilepsia.
[46] R. Barrett,et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.
[47] R. Barrett,et al. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.
[48] Patrick Couvreur,et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. , 2005, Bioconjugate chemistry.
[49] Kevin J. Kelly,et al. Gabapentin , 1998, Neuropsychobiology.
[50] M. E. Hernández,et al. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model , 2006, Epilepsy Research.
[51] D D Allen,et al. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.
[52] Jean-Pierre Benoit,et al. Active targeting of brain tumors using nanocarriers. , 2007, Biomaterials.
[53] K. Avgoustakis,et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.
[54] M. Radeke,et al. Distribution of Intracerebral Ventricularly Administered Neurotrophins in Rat Brain and Its Correlation with Trk Receptor Expression , 1994, Experimental Neurology.
[55] Amarnath Sharma,et al. Liposomes in drug delivery: Progress and limitations , 1997 .
[56] J. Moore,et al. Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy , 2004, The Annals of pharmacotherapy.
[57] H. García-Rivello,et al. Neuronal and Glial Expression of the Multidrug Resistance Gene Product in an Experimental Epilepsy Model , 2004, Cellular and Molecular Neurobiology.
[58] C. Nicholson,et al. Cell cavities increase tortuosity in brain extracellular space. , 2005, Journal of theoretical biology.
[59] M. V. Catania,et al. Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study , 2006, Neurological Sciences.
[60] W. Mark Saltzman,et al. Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.
[61] G. Barratt,et al. Therapeutic applications of colloidal drug carriers. , 2000, Pharmaceutical science & technology today.
[62] Y. Cai,et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[63] G. Khuller,et al. Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study. , 2001, International journal of antimicrobial agents.
[64] E. Aronica,et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. , 2007, Brain : a journal of neurology.
[65] L. Fenart,et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.
[66] M. Bilsky,et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. , 2000, Neurosurgery.
[67] K. Makino,et al. Incorporation of water-soluble drugs in PLGA microspheres. , 2007, Colloids and surfaces. B, Biointerfaces.
[68] W. Löscher,et al. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2005 .
[69] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[70] P. Couvreur,et al. Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.
[71] T. Minko,et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[72] W. Hennink,et al. Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. , 2007, Bioconjugate chemistry.
[73] M. Gomori,et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. , 2000, Journal of neurosurgery.
[74] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[75] W. Pardridge. Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.
[76] M. Brightman,et al. Permeable Endothelium and the Interstitial Space of Brain , 2000, Cellular and Molecular Neurobiology.
[77] R. Aird. A study of intrathecal, cerebrospinal fluid-to-brain exchange , 1984, Experimental Neurology.
[78] J. Parker. Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein , 2003 .
[79] Norberto Garcia-Cairasco,et al. EEG wavelet analyses of the striatum–substantia nigra pars reticulata–superior colliculus circuitry: Audiogenic seizures and anticonvulsant drug administration in Wistar audiogenic rats (War strain) , 2006, Epilepsy Research.
[80] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[81] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[82] F. Szoka,et al. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.
[83] J. Huwyler,et al. Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[84] V. Levin,et al. High-Grade Gliomas: Diagnosis and Treatment , 2007 .
[85] M. Thom,et al. Multidrug-resistance protein 1 in focal cortical dysplasia , 2001, The Lancet.
[86] A. Billiau,et al. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice , 2005, Archives of Virology.
[87] W. Mark Saltzman,et al. Building drug delivery into tissue engineering design , 2002, Nature Reviews Drug Discovery.
[88] Charles Nicholson,et al. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[89] Joseph D. Andrade,et al. Protein—surface interactions in the presence of polyethylene oxide , 1991 .
[90] Y. Eto,et al. Liposome targeting to mouse brain: mannose as a recognition marker. , 1988, Biochemical and biophysical research communications.
[91] Robert S Fisher,et al. Potential New Methods for Antiepileptic Drug Delivery , 2002, CNS drugs.
[92] D. Kraemer,et al. Association of Total Dose Intensity of Chemotherapy in Primary Central Nervous System Lymphoma (Human Non-Acquired Immunodeficiency Syndrome) and Survival , 2001, Neurosurgery.
[93] Robert S. Fisher,et al. Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold , 2007, Neuroscience Letters.
[94] L. Martinian,et al. Vascular colocalization of P‐glycoprotein, multidrug‐resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies , 2006, Neuropathology and applied neurobiology.
[95] Y. Tabata,et al. Intraocular sustained drug delivery using implantable polymeric devices. , 2005, Advanced drug delivery reviews.
[96] P. Couvreur,et al. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting , 1999 .
[97] W. Saltzman,et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. , 1998, Cancer research.
[98] J. Fechner,et al. Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection) - a water-soluble propofol prodrug. , 2008, Handbook of experimental pharmacology.
[99] P. Lockman,et al. The blood-brain barrier choline transporter as a brain drug delivery vector. , 2003, Life sciences.
[100] René H. Levy,et al. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) , 2007, Epilepsy Research.
[101] D. Trombetta,et al. Design and Characterization of Liposomes Containing Long-Chain N-AcylPEs for Brain Delivery: Penetration of Liposomes Incorporating GM1 into the Rat Brain , 2002, Pharmaceutical Research.
[102] M R Gaab,et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. , 2004, Clinical neuropathology.
[103] E. Aronica,et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors , 2003, Neuroscience.
[104] D. Covell,et al. Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid. , 1985, The American journal of physiology.
[105] M. Haluska,et al. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. , 2004, Clinical journal of oncology nursing.
[106] Alan Connelly,et al. EEG‐fMRI in Children with Pharmacoresistant Focal Epilepsy , 2007, Epilepsia.
[107] J. Huwyler,et al. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. , 1997, The Journal of pharmacology and experimental therapeutics.
[108] R. Gonzalez,et al. The determination of dielectric constants of mixtures used in the treatment of epilepsy and the encapsulation of phenytoin in a titania matrix , 2007 .
[109] R. A. Jain,et al. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.
[110] Bernd Büchner,et al. Carbon nanotube based biomedical agents for heating, temperature sensoring and drug delivery , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[111] Mansoor M. Amiji,et al. Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.
[112] R. Cavalli,et al. Intravenous Administration to Rabbits of Non-stealth and Stealth Doxorubicin-loaded Solid Lipid Nanoparticles at Increasing Concentrations of Stealth Agent: Pharmacokinetics and Distribution of Doxorubicin in Brain and Other Tissues , 2002, Journal of drug targeting.
[113] W. Pardridge. Transport of small molecules through the blood-brain barrier: biology and methodology. , 1995, Advanced drug delivery reviews.
[114] M. Krzyżanowski,et al. New generation of valproic acid. , 2004, Polish journal of pharmacology.
[115] G. Luijtelaar,et al. Absence seizures are reduced by the enhancement of GABA-ergic inhibition in the hippocampus in WAG/Rij rats , 2007, Neuroscience Letters.
[116] A. Hart,et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. , 2004, European journal of cancer.
[117] O. Lindvall,et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices , 2004, Experimental Brain Research.
[118] P. Couvreur,et al. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles , 2008, Cancer Chemotherapy and Pharmacology.
[119] J. Kreuter,et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.